Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease

References

• Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
   PubMed Web of Science ®Google Scholar
• Rosner MH. Measuring risk in end-stage renal disease: is N-terminal pro brain natriuretic peptide a useful marker? Kidney Int 2007;71:481–3.
   PubMed Web of Science ®Google Scholar
• Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007;71:548–54.
   PubMed Web of Science ®Google Scholar
• Wang AY-M, Lam CW-K, Yu CM, Wang M, Chan IH-S, Zhang Y, N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007;18:321–30.
   PubMed Web of Science ®Google Scholar
• Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007;50:1009–19.
   PubMed Web of Science ®Google Scholar
• Madsen LH, Ladefoged S, Hildebrandt P, Atar D. Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. Acute Card Care 2008;10:173–80.
   PubMedGoogle Scholar
• Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106:2941–5.
   PubMed Web of Science ®Google Scholar
• Apple FS, Jaffe AS, Herzog CA. Letter regarding article by Khan, et al, “Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis”. Circulation 2006;113:e775.
   PubMed Web of Science ®Google Scholar
• Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279–85.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–9.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109–23.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–72.
   PubMed Web of Science ®Google Scholar
• May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109–20.
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107–16.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Gerber Y, Weston SA, Killian JM, Redfield MM, Roger VL. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2009;2:393–400.
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005;67:2330–7.
   PubMed Web of Science ®Google Scholar
• deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290:353–9.
   PubMed Web of Science ®Google Scholar
• Wang AY, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem 2007;53:882–9.
   PubMed Web of Science ®Google Scholar
• Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000;102:1964–9.
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 2003;63:1462–7.
   PubMed Web of Science ®Google Scholar
• Cooper BA, Penne EL, Bartlett LH, Pollock CA. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004;43:61–6.
   PubMed Web of Science ®Google Scholar
• Freda BJ, Tang WH, Van LF, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40:2065–71.
   PubMed Web of Science ®Google Scholar
• Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407–14.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Tian L. Predicting cardiovascular risk: so what do we do now? Arch Intern Med 2006;166:1342–4.
   PubMedGoogle Scholar
• Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ 2009;338:b375.
   PubMed Web of Science ®Google Scholar